Table 3 Death before anti-TB treatment among pulmonary TB patients with and without NAA test.
From: Nucleic acid amplification tests reduce delayed diagnosis and misdiagnosis of pulmonary tuberculosis
No NAA | With NAA | p valuea | NAA strategy | p valueb | p valuec | p valued | ||
|---|---|---|---|---|---|---|---|---|
Frontline NAA | Add-on NAA | |||||||
Overall population | ||||||||
Case number | 1193 | 999 | 282 | 717 | ||||
Death before treatment | 53 (4.4%) | 16 (1.6%) | < 0.001 | 2 (0.7%) | 14 (2.0%) | 0.003 | 0.004 | 0.159 |
Smear-positive cohort | ||||||||
Case number | 222 | 750 | 188 | 562 | ||||
Death before treatment | 3 (1.4%) | 11 (1.5%) | 0.368 | 1 (0.5%) | 10 (1.8%) | 0.400 | 0.672 | 0.308 |
Smear-negative cohort | ||||||||
Case number | 971 | 249 | 94 | 155 | ||||
Death before treatment | 50 (5.1%) | 5 (2.0%) | 0.033 | 1 (1.1%) | 4 (2.6%) | 0.077 | 0.165 | 0.653 |
